Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 254

    1.

    Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors.

    Desai J, Yassa L, Marqusee E, George S, Frates MC, Chen MH, Morgan JA, Dychter SS, Larsen PR, Demetri GD, Alexander EK.

    Ann Intern Med. 2006 Nov 7;145(9):660-4.PMID: 17088579 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Summaries for patients. Underactive thyroid function after treatment with sunitinib for gastrointestinal cancer.

    [No authors listed]

    Ann Intern Med. 2006 Nov 7;145(9):I44. No abstract available. PMID: 17088575 [PubMed - indexed for MEDLINE]Related articlesFree article

    3.

    A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake.

    Mannavola D, Coco P, Vannucchi G, Bertuelli R, Carletto M, Casali PG, Beck-Peccoz P, Fugazzola L.

    J Clin Endocrinol Metab. 2007 Sep;92(9):3531-4. Epub 2007 Jun 26.PMID: 17595247 [PubMed - indexed for MEDLINE]Related articlesFree article

    4.

    Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity.

    Wong E, Rosen LS, Mulay M, Vanvugt A, Dinolfo M, Tomoda C, Sugawara M, Hershman JM.

    Thyroid. 2007 Apr;17(4):351-5.PMID: 17465866 [PubMed - indexed for MEDLINE]Related articles

    5.

    The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation.

    Wolter P, Stefan C, Decallonne B, Dumez H, Bex M, Carmeliet P, Schöffski P.

    Br J Cancer. 2008 Aug 5;99(3):448-54.PMID: 18665181 [PubMed - indexed for MEDLINE]Related articlesFree article

    6.

    Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib.

    Rini BI, Tamaskar I, Shaheen P, Salas R, Garcia J, Wood L, Reddy S, Dreicer R, Bukowski RM.

    J Natl Cancer Inst. 2007 Jan 3;99(1):81-3.PMID: 17202116 [PubMed - indexed for MEDLINE]Related articlesFree article

    7.

    Thyrotoxicosis during sunitinib treatment for renal cell carcinoma.

    Grossmann M, Premaratne E, Desai J, Davis ID.

    Clin Endocrinol (Oxf). 2008 Oct;69(4):669-72. Epub 2008 Apr 3.PMID: 18394019 [PubMed - indexed for MEDLINE]Related articles

    8.

    Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors.

    Adams VR, Leggas M.

    Clin Ther. 2007 Jul;29(7):1338-53. Review.PMID: 17825686 [PubMed - indexed for MEDLINE]Related articles

    9.

    Sunitinib: new drug. For some gastrointestinal stromal tumours.

    [No authors listed]

    Prescrire Int. 2007 Aug;16(90):138-41.PMID: 17724833 [PubMed - indexed for MEDLINE]Related articles

    10.

    Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate.

    Telli ML, Witteles RM, Fisher GA, Srinivas S.

    Ann Oncol. 2008 Sep;19(9):1613-8. Epub 2008 Apr 23.PMID: 18436521 [PubMed - indexed for MEDLINE]Related articlesFree article

    11.

    Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy.

    Torino F, Corsello SM, Longo R, Barnabei A, Gasparini G.

    Nat Rev Clin Oncol. 2009 Apr;6(4):219-28. Review.PMID: 19333228 [PubMed - indexed for MEDLINE]Related articles

    12.

    Tyrosine kinase inhibitors and the thyroid as both an unintended and an intended target.

    Vetter ML, Kaul S, Iqbal N.

    Endocr Pract. 2008 Jul-Aug;14(5):618-24. Review.PMID: 18753108 [PubMed - indexed for MEDLINE]Related articles

    13.

    Food and Drug Administration drug approval summary: Sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma.

    Rock EP, Goodman V, Jiang JX, Mahjoob K, Verbois SL, Morse D, Dagher R, Justice R, Pazdur R.

    Oncologist. 2007 Jan;12(1):107-13.PMID: 17227905 [PubMed - indexed for MEDLINE]Related articlesFree article

    14.

    Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib.

    Chu TF, Rupnick MA, Kerkela R, Dallabrida SM, Zurakowski D, Nguyen L, Woulfe K, Pravda E, Cassiola F, Desai J, George S, Morgan JA, Harris DM, Ismail NS, Chen JH, Schoen FJ, Van den Abbeele AD, Demetri GD, Force T, Chen MH.

    Lancet. 2007 Dec 15;370(9604):2011-9.PMID: 18083403 [PubMed - indexed for MEDLINE]Related articlesFree article

    15.

    Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.

    Burstein HJ, Elias AD, Rugo HS, Cobleigh MA, Wolff AC, Eisenberg PD, Lehman M, Adams BJ, Bello CL, DePrimo SE, Baum CM, Miller KD.

    J Clin Oncol. 2008 Apr 10;26(11):1810-6. Epub 2008 Mar 17.PMID: 18347007 [PubMed - indexed for MEDLINE]Related articles

    16.

    Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial.

    Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, McArthur G, Judson IR, Heinrich MC, Morgan JA, Desai J, Fletcher CD, George S, Bello CL, Huang X, Baum CM, Casali PG.

    Lancet. 2006 Oct 14;368(9544):1329-38.PMID: 17046465 [PubMed - indexed for MEDLINE]Related articles

    17.

    Benefit-risk assessment of sunitinib in gastrointestinal stromal tumours and renal cancer.

    Theou-Anton N, Faivre S, Dreyer C, Raymond E.

    Drug Saf. 2009;32(9):717-34. doi: 10.2165/00002018-200932090-00003. Review.PMID: 19670913 [PubMed - indexed for MEDLINE]Related articles

    18.

    Heart failure associated with sunitinib malate: a multitargeted receptor tyrosine kinase inhibitor.

    Khakoo AY, Kassiotis CM, Tannir N, Plana JC, Halushka M, Bickford C, Trent J 2nd, Champion JC, Durand JB, Lenihan DJ.

    Cancer. 2008 Jun;112(11):2500-8.PMID: 18386829 [PubMed - indexed for MEDLINE]Related articlesFree article

    19.

    Sunitinib (sutent)-induced thyrotoxicosis due to destructive thyroiditis: a case report.

    Faris JE, Moore AF, Daniels GH.

    Thyroid. 2007 Nov;17(11):1147-9.PMID: 17714037 [PubMed - indexed for MEDLINE]Related articles

    20.

    Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma.

    Goodman VL, Rock EP, Dagher R, Ramchandani RP, Abraham S, Gobburu JV, Booth BP, Verbois SL, Morse DE, Liang CY, Chidambaram N, Jiang JX, Tang S, Mahjoob K, Justice R, Pazdur R.

    Clin Cancer Res. 2007 Mar 1;13(5):1367-73. Review.PMID: 17332278 [PubMed - indexed for MEDLINE]Related articlesFree article

    Supplemental Content

    Find related data